Thursday's HotCopper trends: Second Amplia response, Race combo dosing | June 19

19 Jun 2025 12:58 (AEST)

Amplia Therapeutics (ASX:ATX) has been the most watched on HotCopper forums through today after huge results from its ACCENT trials set up to look into how its FAK inhibitor, Narmafotinib, combats cancer.

Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.

The bonza results have seen a second patient (from 55) record a complete response, where the pancreatic cancer patient saw all tumour lesions disappear.

Also trending: Race Oncology (ASX:RAC), after the biopharmaceutical company managed “successful and safe” combo dosing for its first patient with RC220 plus doxorubicin in its Phase One trial in advanced solid tumour patients.

Alligator Energy (ASX:AGE) has rounded out the most-discussed on the HotCopper forums after heading into a trading halt. Sales will resume on Monday.

And finally, the ASX 200 is just barely in the red today after an -8.7pt dip.

Join the discussion: See what’s trending right now on Australia’s largest stock forum and be part of the conversations that move the markets.

The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please clickhere.


arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.